melanoma

AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression
AACR: Roche's Tecentriq, added to Cotellic and Zelboraf, stalls melanoma progression
Fierce Pharma
Roche
Tecentriq
Cotellic
Zelboraf
melanoma
AACR
Flag link:
Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients
Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients
Pharmaceutical Business Review
Elios Therapeutics
clinical trials
vaccines
melanoma
Flag link:
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Fierce Biotech
melanoma
Nektar Therapeutics
bempegaldesleukin
Flag link:
Nektar shows durability of Opdivo combo in 18-month update
Nektar shows durability of Opdivo combo in 18-month update
Fierce Biotech
Nektar Therapeutics
NKTR-214
Opdivo
Bristol-Myers Squibb
melanoma
clinical trials
Flag link:
Led by BioNTech, six biotechs line up for October IPOs
Led by BioNTech, six biotechs line up for October IPOs
Endpoints
IPOs
MRNA
melanoma
inebilizumab
NMOSD
blood cancer
solid tumors
BioNTech
ADC Therapeutics
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
Monopar Therapeutics
Flag link:
Skin Cancer Diagnostics Company Files for $57 Million IPO
Skin Cancer Diagnostics Company Files for $57 Million IPO
CP Wire
Castle Biosciences
melanoma
IPOs
diagnostics
Flag link:
Skin Cancer Diagnostics Company Files for $57 Million IPO
Castle Biosciences
melanoma
IPOs
diagnostics
Flag link:
Complete response rate in Nektar melanoma trial hits 34%
Complete response rate in Nektar melanoma trial hits 34%
Fierce Biotech
Nektar
NKTR-214
Opdivo
ASCO 2019
melanoma
Flag link:
Keytruda gets okay from FDA for adjuvant melanoma
Keytruda gets okay from FDA for adjuvant melanoma
Pharmaforum
FDA
Merck
adjuvant melanoma
melanoma
Keytruda
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Merck bags adjuvant okay for Keytruda in melanoma
Merck bags adjuvant okay for Keytruda in melanoma
Pharmaforum
Merck
Europe
Keytruda
melanoma
Flag link:
OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout
OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout
Endpoints
OncoSec
Merck
Keytruda
Tavo
melanoma
Flag link:
Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain
Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain
New York Times, NY
melanoma
Opdivo
clinical trials
Bristol-Myers Squibb
Flag link:
Opdivo Approved in Europe for Additional Use in Melanoma Patients
Opdivo Approved in Europe for Additional Use in Melanoma Patients
CP Wire
Opdivdo
Bristol-Myers Squibb
melanoma
advanced melanoma
Europe
Flag link:
Opdivo Approved in Europe for Additional Use in Melanoma Patients
Opdivdo
Bristol-Myers Squibb
melanoma
advanced melanoma
Flag link:
Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
CP Wire
Merck
Keytruda
melanoma
China
Flag link:
Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Merck
Keytruda
melanoma
Flag link:
Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi
Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi
Endpoints
Array Biopharma
binimetinib
Mektovi
Braftovi
melanoma
Flag link:
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Forbes
Nektar
Bristol-Myers Squibb
NKTR-214
ASCO 2018
melanoma
renal cell carcinoma
urothelial cancer
Flag link:

Pages